Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer

• ClinicalTrials.gov Identifier: NCT02448810
• Recruitment Status: Terminated
• First Posted: May 20, 2015
• Results First Posted: March 19, 2018
• Last Update Posted: May 25, 2021
• Sponsor: Baxalta now part of Shire
• Information provided by (Responsible Party): Takeda ( Baxalta now part of Shire )

Study Description

Brief Summary:

The purpose of this study is to evaluate the safety and tolerability of BAX69 in combination with 5-fluorouracil (5-FU)/leucovorin (LV) or panitumumab to determine the recommended phase II dose (RP2D) of each combination; and to compare the efficacy between BAX69 in combination with 5-FU/LV for subjects with KRAS or NRAS mutated tumor (mt) or panitumumab, for subjects with KRAS and NRAS wild type tumor (wt) and standard of care (SoC) per investigator choice as third or fourth treatment line in subjects with progressive measurable metastatic colorectal cancer (mCRC).

Condition or disease	Intervention/treatment	Phase
Metastatic Colorectal Cancer	Biological: BAX69 + infusional 5-FU/LV; Biological: BAX69 + panitumumab; Biological: BAX69 + 5-FU/LV; Drug: Standard of Care; Biological: Standard of Care	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 115 participants
• Allocation: Randomized
• Intervention Model: Factorial Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
• Actual Study Start Date: June 15, 2015
• Actual Primary Completion Date: February 15, 2017
• Actual Study Completion Date: February 15, 2017

Arms and Interventions

Arm	Intervention/treatment
Experimental: Part 1: Subjects with mutated tumor (mt) (KRAS or NRAS); Subjects stratified according to their mutation status.	Biological: BAX69 + infusional 5-FU/LV; Study Part 1: Safety Run-in; Administered weekly as part of a 4 week treatment cycle; Intravenous injection; Other Names: Macrophage Migration Inhibitory Factor Antibody (Anti-MIF); Imalumab
Experimental: Part 1: Subjects with wild-type (wt) tumor (KRAS and NRAS wt); Subjects stratified according to their mutation status.	Biological: BAX69 + panitumumab; Study Part 1: Safety Run-in; Administered weekly as part of a 4 week treatment cycle; Intravenous injection; Other Names: Imalumab; Anti-MIF
Experimental: Part 2: Subjects with KRAS or NRAS mutated; Subjects stratified according to their mutation status.	Biological: BAX69 + 5-FU/LV; Study Part 2: Administered weekly as part of a 4 week treatment cycle •Intravenous injection; Other Names: Imalumab; Anti-MIF
Experimental: Part 2: Subjects with KRAS and NRAS wt tumor; Subjects stratified according to their mutation status.	Biological: BAX69 + panitumumab; Study Part 2: Administered weekly as part of a 4 week treatment cycle •Intravenous injection; Other Names: Imalumab; Anti-MIF
Active Comparator: Part 2: Standard of Care- Subjects with KRAS or NRAS mutated; Subjects stratified according to their mutation status.	Drug: Standard of Care; Investigator's choice; Dose according to drug label
Active Comparator: Part 2: Standard of Care- Subjects with KRAS and NRAS wt tumor; Subjects stratified according to their mutation status.Subjects stratified according to their mutation status.	Biological: Standard of Care; Investigator's choice; Dose according to drug label; Choice includes panitumumab in KRAS &NRAS wt group only

Outcome Measures

Primary Outcome Measures :

1. Part 2: Progression-Free Survival (PFS) [ Time Frame: From start of the study up to safety follow-up visit occurred (30 [-/+7]) days after the last dose of study treatment or until disease progression ]
   PFS was defined as time between treatment initiation and tumor progression (per Response Evaluation Criteria in Solid Tumors [RECIST] v1.1 criteria) or death from any cause, with censoring of participants who were lost to follow-up or withdrew consent.
2. Part 1: Number of Participants With Occurrence of Dose Limiting Toxicity (DLT) [ Time Frame: From start of study treatment up to 28 days ]
   DLT was defined as any drug-related treatment-emergent adverse event (TEAE) (graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v4.03) that occurs during the first 28 days after treatment start and that meets any of the following criteria: i) Any >= Grade 3 non-hematologic toxicity (excluding: mucositis/stomatitis of Grade 3; diarrhea of <3 days duration; nausea and vomiting <3 days duration; fatigue of <7 days duration; alopecia; single laboratory value out of the normal range that has no clinical significance and that resolves to <= Grade 2 with adequate measures within 7 days) ii) Any Grade 4 hematologic toxicity (excluding: grade 4 neutropenia lasting for <= 5 days; isolated grade 4 lymphocytopenia) iii) Grade 3 febrile neutropenia iv) Grade 3 thrombocytopenia associated with bleeding v) Any life-threatening complication or abnormality not covered in NCI CTCAEv4.03.

Secondary Outcome Measures :

1. Number of Participants With Occurrence of Binding and/or Neutralizing Anti-imalumab Antibodies [ Time Frame: From start of study drug administration up to end of treatment (EOT) (approximately 21 Months) ]
   Number of participants with occurrence of binding and/or neutralizing anti-imalumab antibodies were reported.
2. Number of Participants With Incidence of Infusion Reactions After Imalumab Administration [ Time Frame: From start of study drug administration up to EOT (approximately 21 Months) ]
   Infusion reaction was defined as any relevant sign or symptom occurring during or after imalumab infusion and considered by the investigator as an infusion reaction.
3. Number of Participants With Serious Adverse Events (SAEs) and Treatment-emergent Adverse Events (TEAEs) [ Time Frame: From start of study drug administration up to EOT (approximately 21 Months) ]
   An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any AE that results in any of the following outcomes: death, a life-threatening event, inpatient hospitalization or prolongation of an existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, a congenital anomaly/birth defect, other medically important events based upon appropriate medical judgement. TEAEs was defined as any event not present prior to the initiation of the treatments or any event already present that worsens in either intensity or frequency following exposure to the treatments.
4. Number of Participants With Response Evaluation According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 [ Time Frame: Day 28 of Cycle 2 followed by every 2 Cycles of 28 day Cycles: Day 56, Day 112, Day 168 and Day 224 ]
   Number of participants with response evaluation according to RECIST v1.1 was evaluated according to complete response (CR): disappearance of all target and non-target lesions and no new lesions; partial response (PR): >= 30 percent (%) decrease in the sum of diameters of target lesions (compared to baseline) and no new lesions; stable disease (SD): neither sufficient shrinkage to qualify as a response nor sufficient growth to qualify as progression; progressive disease (PD): >= 20% increase in the sum of diameters of target lesions and an absolute increase in sum of diameters of >=5 millimeter (mm) (compared to the previous minimum sum) or progression of a new lesion.
5. Overall Survival [ Time Frame: From start of study drug administration up to EOT (approximately 21 Months) ]
   Overall survival was defined as the time from randomization until death due to any cause. Here, number of participants analyzed was based on the number of participants who underwent death.
6. Change From Baseline for Quality of Life (QoL) Measure - European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) [ Time Frame: Baseline, 21 Months (EOT) up to follow-up ]
   EORTC QLQ-C30 was a validated instrument used to measure QoL and assess symptoms and side effects of treatment and the impact on everyday life.The QLQ-C30 was composed of: A) 5 multi-item functioning scales(physical, role, social, emotional and cognitive), that were answered on a 4-point scale (1=Not at all,2=A Little,3=Quite a Bit,4=Very Much). Each score range from 0 to 100 with a higher score representing a higher level of functioning and a better QoL. B) A global health status/QoL scale that was answered on a 7-point scale (1=Very Poor to 7=Excellent). Each score range from 0 to 100 with a higher score representing a better QoL. C) 9 symptom scales(fatigue, nausea/vomiting,pain,financial impact/difficulties,appetite loss,diarrhea, constipation,sleep disturbance/insomnia and dyspnea), that were answered on a 4-point scale (1=Not at all,2=A Little,3=Quite a Bit,4=Very Much). Each score range from 0 to 100 with a higher score representing a greater degree of symptoms and a worse QoL.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Provision of a signed informed consent
2. Male and female subjects 18 years of age and older at the time of screening
3. Subjects who progressed after receiving at least 2, but no more than 3, prior SoC treatment lines
4. Anticipated life expectancy >3 months at the time of screening
5. Weight between 40 kg and 180 kg
6. Histologically or cytologically confirmed diagnosis of CRC
7. Metastatic CRC not amenable to surgical resection
8. Known KRAS and NRAS mutation status (if unknown status for either of these genes, and no archival tissues is available, a fresh tumor biopsy will be made)
9. At least 1 measurable lesion as defined by RECIST v1.1
10. ECOG PS of 0-2

11. Adequate hematological function, defined as:

    1. Platelet count ≥ 100,000/μL
    2. Prothrombin time and activated partial thromboplastin time (aPTT) < 1.5 times the upper limit of normal (ULN)
    3. Absolute neutrophil count (ANC) ≥ 1,000/μL
    4. Hemoglobin ≥ 9 g/dL, without the need for transfusion in the 2 weeks prior to screening
12. Adequate renal function, defined as serum creatinine ≤ 2.0 times ULN and creatinine clearance > 50 mL/min

13. Adequate liver function, defined as:

    1. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)

       ≤ 2.5 times ULN for subjects without liver metastases, or ≤ 5 times ULN in the presence of liver metastases

    2. Bilirubin ≤ 2.0 times ULN, unless subject has known Gilbert's syndrome
14. Adequate venous access
15. For female subjects of childbearing potential, the subject presents with a negative serum pregnancy test at screening and agrees to employ 2 forms of adequate birth control measures, including at least 1 barrier method (eg, diaphragm with spermicidal jelly or foam, or [for male partner] condom) throughout the course of the study and for at least 90 days after the last administration of BAX69. Other acceptable contraceptive measures include birth control pills/patches or intrauterine devices
16. For male subjects, the subject must agree to use adequate contraceptive measures including at least 1 barrier method (eg, condom with spermicidal jelly or foam and [for the female partner] diaphragm with spermicidal jelly or foam, birth control pills/patches, or intrauterine device) and abstain from sperm donation throughout the course of the study and for at least 90 days after the last administration of BAX69
17. Subject is willing and able to comply with the requirements of the protocol.

Exclusion Criteria:

1. Known central nervous system metastases
2. Prior malignancy(s) within the past 3 years, with the exception of curatively treated basal or squamous cell carcinoma of the skin, locally advanced prostate cancer, ductal carcinoma in situ of breast, in situ cervical carcinoma and superficial bladder cancer
3. Prior treatment with panitumumab for subjects with KRAS and NRAS wt tumor
4. Residual AE from previous treatment > Grade 1
5. Prior intolerance to fluoropyrimidine for subjects with KRAS or NRAS mut tumor
6. Myocardial infarction within 6 months prior to C1D1, and/or prior diagnoses of congestive heart failure (New York Heart Association Class III or IV), unstable angina, unstable cardiac arrhythmia requiring medication; and/or the subject is at risk for polymorphic ventricular tachycardia (eg, hypokalemia, family history or long QT syndrome)
7. Uncontrolled hypertension defined as systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg confirmed upon repeated measures
8. LVEF < 40% as determined by echocardiogram performed at screening or within 90 days prior to C1D1
9. QT/QTc interval > 450 msec, as determined by screening ECG performed no earlier than 1 week before C1D1
10. Prior anti-tumor therapy (chemotherapy, radiotherapy, antibody therapy, molecular targeted therapy, retinoid therapy or hormonal therapy) within 4 weeks prior to C1D1.
11. Major surgery within 4 weeks prior to C1D1
12. Active joint inflammation or history of inflammatory arthritis or other immune disorder involving joints
13. Active infection involving IV antibiotics within 2 weeks prior to C1D1
14. Known history of, or active hepatitis B virus (HBV), hepatitis C virus (HCV) or active tuberculosis
15. Known history of human immunodeficiency virus (HIV) type 1/2 or other immunodeficiency disease
16. Subject has received a live vaccine within 4 weeks prior to C1D1
17. Known hypersensitivity to any component of recombinant protein production by CHO cells
18. Exposure to an investigational product or investigational device in another clinical study within 4 weeks prior to C1D1, or is scheduled to participate in another clinical study involving an investigational product or device during the course of this study
19. Subject is nursing or intends to begin nursing during the course of the study
20. Any disorder or disease, or clinically significant abnormality on laboratory or other clinical test(s) (eg, blood tests, ECG), that in medical judgment of the investigator may impede the subject's participation in the study, pose increased risk to the subject, and/or confound the results of the study
21. Subject is a family member or employee of the investigator

Contacts and Locations

Locations

United States, Florida

Hematology Oncology Associates of the Treasure Coast

Port Saint Lucie, Florida, United States, 34952

United States, Illinois

Joliet Oncology-Hematology Associates, Ltd.

Joliet, Illinois, United States, 60435

United States, Indiana

Indiana University Health

Goshen, Indiana, United States, 46526

United States, Maryland

Maryland Oncology Hematology, P.A.

Rockville, Maryland, United States, 20850

United States, Missouri

Washington University School of Medicine

Saint Louis, Missouri, United States, 63110

United States, New York

Montefiore Einstein Center for Cancer Care

Bronx, New York, United States, 10461

Mount Sinai Beth Israel

New York, New York, United States, 10003

United States, Oklahoma

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, United States, 73104

United States, South Carolina

Medical University of South Carolina (MUSC)

Charleston, South Carolina, United States, 29412

United States, Tennessee

The Jones Clinic, PC

Germantown, Tennessee, United States, 38138

United States, Texas

Mary Crowley Cancer Research Center

Dallas, Texas, United States, 75230

CTRC at University of Texas Health Science Center

San Antonio, Texas, United States, 78229

Sponsors and Collaborators

Baxalta now part of Shire

Investigators

• Study Director: Study Director; Takeda

  Study Documents (Full-Text)

Documents provided by Takeda ( Baxalta now part of Shire ):

Study Protocol  [PDF] May 9, 2016

Statistical Analysis Plan  [PDF] October 10, 2016

More Information

• Responsible Party: Baxalta now part of Shire
• ClinicalTrials.gov Identifier: NCT02448810
• Other Study ID Numbers: 391401; 2015-000896-28 ( EudraCT Number )
• First Posted: May 20, 2015
• Results First Posted: March 19, 2018
• Last Update Posted: May 25, 2021
• Last Verified: May 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Yes
• Plan Description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
• Supporting Materials: Study Protocol; Statistical Analysis Plan (SAP); Informed Consent Form (ICF); Clinical Study Report (CSR)
• Access Criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
• URL: https://vivli.org/ourmember/takeda/

Additional relevant MeSH terms:

Colorectal Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases; Fluorouracil; Panitumumab; Antimetabolites; Molecular Mechanisms of Pharmacological Action; Antimetabolites, Antineoplastic; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Physiological Effects of Drugs; Antineoplastic Agents, Immunological